Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial by Vergote, Ignace, PhD, Scambia, Giovanni, MD, O'Malley, David M, MD, Van Calster, Ben, PhD, Park, Sang-Yoon, PhD, del Campo, Josep M, MD, Meier, Werner, PhD, Bamias, Aristotelis, PhD, Colombo, Nicoletta, MD, Wenham, Robert M, MD, Covens, Al, MD, Marth, Christian, PhD, Raza Mirza, Mansoor, MD, Kroep, Judith R, MD, Ma, Haijun, PhD, Pickett, Cheryl A, PhD, Monk, Bradley J, MD

Get full text